Faculty Bibliography

OBJECTIVE:Prior authorization (PA) is a process used by payers for safety and cost savings purposes, but it has received criticism for being time-consuming and costly because of administrative burden. Our study evaluated efficacy of PA applied to in-office lower extremity superficial venous procedures. METHODS:All in-office lower extremity venous procedures scheduled to be performed at our institution in 2017 were included in the study. Variables of interest were type of procedure, initial PA status (approved or denied), rationale for the decision, and final status after appeal. Cost analysis was performed using Centers for Medicare and Medicaid Services allowable rates to approximate billing and reimbursement data (proprietary) as well as calculated using industry averages. RESULTS:For 2017, of 1959 procedures scheduled, 57.9% (n = 1134) required PA. Of these, only 6.1% (n = 69) received initial PA denial, and nearly 40% of the denials (n = 27) were overturned after appeal. Of the 42 denials that were upheld, 15 resulted in cancellations; the remainder were performed by patient self-pay (n = 11) or by the provider pro bono (n = 16). Overturned denials were a result of either submission of incomplete clinical data on initial PA request or insufficient documentation of clinical necessity. When Centers for Medicare and Medicaid Services allowable rates were applied for cost analysis, the denials resulted in <$60,000 payer savings. Administrative expenses totaled >$110,000 when industry standards were applied, which far exceeds any calculated payer savings using the same methods. The 15 denials resulting in procedure cancellations (1.3% of all PAs) could be considered a net savings to the health care system but only approximated a mere $30,000. CONCLUSIONS:Our study demonstrates that PA is not a cost-effective measure for utilization management of outpatient superficial venous procedures when surgeon practices are already well aligned with insurance guidelines. For these physicians and physician groups, the administrative cost associated with the PA process exceeds the savings seen by the insurance companies.

Objective: The purpose of this study was to evaluate the effect of an advanced pneumatic compression device (APCD) on improving symptoms and quality of life in patients with lower extremity lymphedema.
Method(s): A total of 178 patients with lower extremity lymphedema were prospectively enrolled in this multicenter study (four Veterans Administration Hospitals) from 2016 to 2019. This study represents analysis of the first 74 patients who have completed 52 weeks of APCD treatment. Demographics and patient characteristics (limb girth, body mass index, and stage of lymphedema) were collected at baseline. Primary end points included both generic quality of life assessment (36-Item Short Form Health Survey) and a disease-specific measure (Lymphedema Quality of Life questionnaire) at 12, 24, and 52 weeks of follow-up. Secondary end points compared changes in limb circumference and skin assessment (lymphedema stage) at each follow-up interval visit. Complications including cellulitis episodes, number of clinic visits, and hospital admissions associated with cellulitis were recorded for the 52 weeks before enrollment and compared with similar events within the 52 weeks of treatment with APCD.
Result(s): Patient demographics were as follows: mean age, 67.0 +/- 11.4 years; male sex (n = 70); body mass index, 32.8 +/- 5.9 kg/m². Most patients had secondary lymphedema (n = 71 [95.9%]), of which the most common cause was chronic venous insufficiency (n = 53 [71.6%]). The majority of patients presented with stage 1 or stage 2 lymphedema (n = 70 [94.6%]); There was a significant decrease in limb girth noted at 12 weeks compared with baseline (28.1 vs 27.3 cm; P =.002), which then plateaued for the remainder of the study period. The 36-Item Short Form Health Survey showed a trend toward quality of life improvement in all areas at 52 weeks (physical component, 39.9 vs 41.7 [P =.1]; mental component, 49.3 vs 51.3 [P =.2]). Lymphedema Quality of Life questionnaire leg scores showed significant continued improvement at each time point (P <.0001). Of the 74 patients, 18 (24.3%) had a history of cellulitis in the 52 weeks before enrollment compared with 7 (9.5%) after 1 year of APCD treatment (P =.01). Among this cellulitis cohort, there was a significant decrease in number of episodes per patient (0.3 vs 0.1; P =.01), total clinic visits (19 vs 6; P =.0003), number of clinic visits per patient (2.2 vs 0.7; P =.06), and number of hospital admissions per patient (0.05 vs 0.1; P =.047).
Conclusion(s): APCD for treatment of lymphedema appears to result in a continued linear improvement in quality of life at least up to 1 year beyond the initial clinical benefit of decreased limb girth. A significant decrease in the number of episodes of cellulitis as well as fewer associated clinic and hospital visits may explain the noted improvement in quality of life for patients and can represent significant cost savings to the health care system.
Copyright

Background: Validated diagnostic assessment tools such as the Venous Clinical Severity Score (VCSS) and the Clinical Etiologic Anatomic Pathophysiologic (CEAP) help determine how superficial venous disease impacts a patient. No single assessment tool provides accurate scoring for disease severity, and this is most clearly exemplified by the variability seen in C2 patient clinical presentations. This has resulted in inconsistent treatment algorithms, patient care, and payer reimbursement. The purpose of this study was to generate an algorithm that incorporates patient reported scores (VVSymQVR ) and physician reported scores (VCSS) in order to improve stratification for disease severity in C2 patients.
Method(s): Consecutive patients with symptomatic varicose veins were included. They were pooled from the VANISH-1 and VANISH-2 cohorts. VCSS and CEAP were calculated for each patient. Patients completed a 7-day electronic daily diary (VVSymQVR ) to capture the type and severity of symptoms, including-Heaviness, Achiness, Swelling, Throbbing, and Itching (HASTI). The relationship between the VCSS and VVSymQVR scores were evaluated using Pearson's correlation. Frequency distribution analysis was used to classify patients according to VCSS and VVSymQVR .
Result(s): Two-hundred ten patients were identified with C2 disease. Patient demographics were as follows: Female 73%; Age 50 years (mean). Scoring systems revealed VCSS: mean=6.32 (range 3-16); VVSymQVR : mean 8.72 (range 1.29-22.86]. A weak correlation was demonstrated between VCSS and VVSymQVR scores (r=0.22 and P=0.05). Figure 1 depicts the frequency distribution analysis: 61.4% of patients had low VVSymQVR and VCSS scores, indicative of mild symptomatology; 31.3% of patients had increased VCSS (range 7-9) and VVSymQVR scores (mean 10.7), indicative of daily symptoms of moderate severity; and an additional 7.3% of patients had VVSymQVR and VCSS scores that were inconsistent for patients with C2 disease.
Conclusion(s): These data highlight the utility of combining patient reported scores and physician reported scores in order to stratify for disease severity in patients with C2 disease. For patients with combined elevated VCSS (7-9) and VVSymQVR (>9) scores, moderate to severe disease severity is corroborated, and interventional treatment may be indicated. For patients who do not meet the combined criterion of the algorithm, the disease severity is likely mild and conservative therapy such as lifestyle modification and compliance with compression may be the more appropriate treatment. Further prospective evaluation correlated to patient outcomes will help to determine the efficacy of this approach

Spontaneous renal artery dissection (SRAD) is a rare disease with approximately 200 cases reported in the literature. The severity of renal compromise, the anatomic location of the dissection, and the presence of uncontrollable hypertension are used to guide the initial management of SRAD. However, there are no reported guidelines for managing the progression of SRAD after acute failure of medical management. In this case, a 40-year-old man with a recently diagnosed SRAD was managed appropriately with therapeutic anticoagulation, yet presented with progression of his dissection and a new acute renal infarct. A covered endovascular stent was used to successfully control dissection progression and prevent further renal compromise.

BACKGROUND: The Vascular Quality Initiative (VQI) Varicose Vein Registry (VVR) represents a patient-centered database launched in January 2015. Previous work describing overall trends and outcomes of varicose vein procedures across the United States demonstrates a benefit from these procedures. The existing gaps in evidence to support current and future Medicare coverage of varicose vein procedures necessitate further description of clinical outcomes in patients >/=65 years old compared with the population <65 years old. METHODS: This study analyzed prospectively captured anatomic, procedural, and outcome data for all patients in a national cohort of all VQI VVR-participating centers. The VQI VVR database was queried for all patients undergoing varicose vein procedures between January 2015 and July 2016. Preprocedural and postprocedural Clinical, Etiology, Anatomy, and Pathophysiology (CEAP) classification, Venous Clinical Severity Score (VCSS), and patient-reported outcomes (PROs) were compared between patients <65 years and >/=65 years old. Univariate descriptive statistics of demographic and procedural data were performed. Student t-tests were then performed on change in CEAP classification, VCSS score, and PROs (heaviness, achiness, throbbing, swelling, itching, appearance, and impact on work) for each group. RESULTS: There were 4841 varicose vein procedures performed from January 2015 to May 2016. There were 3441 procedures performed in 2691 patients (3631 limbs) in the group <65 years old and 1400 procedures performed in 1068 patients (1467 limbs) in the group >/=65 years old. Truncal veins alone were the most common veins treated in both groups. The majority of patients were white and female in both groups. Most of the demographic characteristics were clinically similar (although statistically different) in both groups with the exception of a higher body mass index in the group <65 years old and a history of bilateral varicose vein treatment, and anticoagulation was more common among patients >/=65 years old. Patients in both groups experienced statistically significant improvement in VCSS, PROs, and CEAP class. There was no difference in overall complications between age groups. CONCLUSIONS: All patients demonstrated an associated improvement in both clinical outcomes (CEAP class, VCSS) and PROs. There was no significant difference in the improvement in CEAP class and VCSS between patients younger and older than 65 years, although the younger population reported greater improvement in PROs. Given these findings, patients older than 65 years appear to benefit from varicose vein procedures and should not be denied interventions on their varicose veins and venous insufficiency on the basis of their age only.